- CA$17.62m
- CA$15.02m
- CA$9.63m
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris And Ceapro Announce Merger Of Equals To Create Diversified Biopharmaceutical Company
Brief: Ceapro Inc. Reports 2023 Third Quarter And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases
Brief: Ceapro Inc Reports Financial Results For Q1 2023 And Provides Corporate Update
Brief: Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan And Avenanthramides Promote Wound Healing And Tissue Regeneration
Brief: Ceapro Appoints Michel Regnier As Senior Vice President
Brief: Ceapro Reports Record 2022 Financial Results And Operational Highlights
Brief: Ceapro Inc Receives Approval From Health Canada To Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets
Brief: Ceapro Reports Third Quarter Financial Results
Brief: Ceapro Announces Positive Data From Bioavailability Studies Evaluating Coq10 Formulations Impregnated With Pgx-Processed Carriers
Brief: Ceapro Inc Reports Record 2022 Second Quarter And Six-Month Financial Results
Brief: Ceapro Reports Q4 and Full Year 2021 Financial Results
Brief: Ceapro Signs Exclusive Long-Term Supply And Distribution Agreement With Symrise
Brief: Ceapro Inc Reports 2021 Third Quarter Financial Results
Brief: Ceapro Reports Preliminary Results From Trial Evaluating High Cholesterol Treatment
Brief: Ceapro Says Its Therapeutic May Be Suitable For Fibrotic Lung Disease And Late Stage COVID-19 Patients
Brief: Ceapro Reports Q2 Earnings Per Share Of 1 Cent
Brief: Ceapro Inc Enters Into Research Collaboration With Angiogenesis Foundation For Beta Glucan And Avenanthramides